Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: neuropathic pain + peripheral neuropathic + lyrica  Related to the article below (Last Update: 7/8/2008)


The Money Times
Lilly gets OK from FDA to treat fibromyalgia
Indianapolis Star, United States - Jun 16, 2008
Cymbalta already is approved to treat major depressive disorder and general anxiety disorder and to manage diabetic peripheral neuropathic pain. ...
Eli Lilly gets FDA approval for Cymbalta for the treatment of ... Forbes
FDA OKs Cymbalta for Fibromyalgia WebMD
Eli Lilly: FDA nod adds gravitas to fibromyalgia Trading Markets (press release)
Pharma Times (subscription)
all 78 news articles »  LLY
FDA Approvals: Cymbalta
Medscape (subscription) - Jun 19, 2008
Duloxetine previously was approved for the treatment of diabetic peripheral neuropathic pain, depression, and generalized anxiety disorder.

In order to show you the most relevant results, we have omitted some entries very similar to the 2 already displayed.
If you like, you can repeat the search with the omitted results included.

Source: Google News

Pregabalin: In the Treatment of Painful Diabetic Peripheral Neuropathy. -
JE Frampton, LJ Scott - Drugs, 2004 - drugs.adisonline.com
... Pregabalin (Lyrica ? 1; 3-isobutyl GABA) is the ... Current Status in Painful Diabetic
Peripheral Neuropathy TOP. ... in the treatment of neuropathic pain (and related ...

[PDF] Antidepressants and antiepileptic drugs for chronic non-cancer pain -
M Maizels, B McCarberg - Am Fam Physician, 2005 - aafp.org
... sensory neuropathy Idiopathic peripheral neuropathy Infection Metabolic ... for diabetic
neuropathy; 300 mg ... Drug Administration for treatment of neuropathic pain. ...

Chronic Neuropathic Pain: Mechanisms, Diagnosis, and Treatment. -
RN Harden - The Neurologist, 2005 - theneurologist.org
... FDA Approves Pfizer's Lyrica? for the Treatment of ... and fluoxetine on pain in diabetic
neuropathy. ... Baron R. Peripheral neuropathic pain: from mechanisms to ...

Pregabalin: In the Treatment of Postherpetic Neuralgia. -
JE Frampton, RH Foster - Drugs, 2005 - drugs.adisonline.com
... 1-3]and pregabalin[3](Lyrica ? )1- the ... of several disorders, including neuropathic
pain [PHN and painful diabetic peripheral neuropathy [DPN]), epilepsy ...

Emerging therapies for neuropathic pain -
SD Collins, IP Chessell - emd, 2005 - Expert Opinion
... efficacy in the treatment of neuropathic pain is unclear ... diabetic neu- ropathy [74]
and peripheral nerve injury ... further study in diabetic neuropathy failed to ...

Pregabalin in neuropathic pain: A more ?pharmaceutically elegant? gabapentin? -
DRP Guay - American Journal of Geriatric Pharmacotherapy, 2005 - Elsevier
... Products in July 2004 for the treatment of peripheral neuropathic pain and as an ...
in December 2004 for the treatment of diabetic peripheral neuropathy (DPN) and ...

Pregabalin: a new agent for the treatment of neuropathic pain -
G Zareba - Drugs Today, 2005 - journals.prous.com
... Pregabalin (Lyrica TM , Pfizer) has recently been ... the first accepted treatment for
neuropathic pain associated with diabetic peripheral neuropathy and post ...

Antiepileptic Drugs in the Treatment of Neuropathic Pain. -
E Eisenberg, Y River, A Shifrin, N Krivoy - Drugs, 2007 - drugs.adisonline.com
... other insults to the peripheral or central somatosensory nervous system. Common
examples of neuropathic pain include diabetic neuropathy, postherpetic neuralgia ...

… : A novel ?-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures … -
DM Tassone, E Boyce, J Guyer, D Nuzum - Clinical Therapeutics, 2007 - Elsevier
... Key words: pregabalin, Lyrica, diabetic peripheral neuropathy, neuropathic pain,
postherpetic neuralgia, partial-onset seizures, epilepsy, generalized anxiety ...

Pregabalin: A New Neuromodulator with Broad Therapeutic Indications -
BF Shneker, JW McAuley - The Annals of Pharmacotherapy, 2005 - Harvey Whitney Books
... The FDA approved pregabalin (Lyrica) for the treatment of neuropathic pain associated
with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN ...

Source: Google Scholar
 
 

Peripheral neuropathic pain: Lyrica is not recommended for use within NHS Scotland

 
 
The Scottish Medicines Consortium ( SMC ) has advised NHS ( National Health Service ) Boards and Area Drug and Therapeutic Committees ( ADTCs ) that Pregabalin ( Lyrica ) is not recommended for use within NHS Scotland for the treatment of peripheral neuropathic pain in adults.

Comparative clinical and cost effectiveness have not been demonstrated.


Evidence on comparative efficacy

Pregabalin is an antiepileptic that decreases central neuronal excitability by binding to an auxillary subunit of a voltage-gated calcium channel in the central nervous system.
It also reduces the release of several neurotransmitters including glutamate, noradrenaline and substance P, though the significance of the latter effects is unknown.

The original submission to the Scottish Medicines Consortium, included data from ten double-blind studies. Five studies recruited patients with diabetes who had glycated haemoglobin ( HbA1C ) less than or equal to 11 percent and distal symmetrical sensorimotor polyneuropathy for more than or equal to 1 year and < 5 years in three studies. Four studies recruited patients with postherpetic neuralgia of more than or equal to 3 and 6 months duration after healing of the herpes zoster skin rash.
A further double-blind trial recruited patients with either diabetic peripheral neuropathy or postherpetic neuralgia.

In all studies patients had a score of more than or equal to 40mm on the 100mm visual analogue pain scale of the Short-Form McGill Pain Questionnaire ( SF-MPQ ) and during the week before randomisation, had at least four daily pain scores more than or equal to 4 assessed on an 11-point scale ( where 0 = no pain and 10 = worst possible pain ).
Patients were randomised to placebo or Pregabalin with one trial including Amitriptyline as an active treatment arm. The primary endpoint, weekly mean pain score ( assessed via the 11-point Likert scale ) at endpoint, was compared in the intention to treat population between placebo and active treatments via an analysis of covariance which adjusted for weekly mean pain score at baseline.

In the trial with an active comparator, Pregabalin 600 mg daily was not associated with a significant difference from placebo in the primary analysis of pain scores at end-point. The difference between Amitriptyline 75mg daily and placebo was significant. This pattern was repeated in two supplementary analyses of pain scores and in a number of secondary end-points including the proportion of patients achieving a response ( more than or equal to 50 percent reduction in pain scores ) and patients’ and clinicians’ global impression of pain. In no endpoint analysis was the result significant for Pregabalin but not Amitriptyline.

Pregabalin 300mg and 600mg were associated with significantly lower weekly mean pain scores at endpoint compared with placebo in all other studies, except for the 300mg dose in a 12-week diabetic neuropathy study. Weekly mean pain scores with Pregabalin 150mg were generally lower than placebo, but differences between this dose and placebo were not consistently significant.
In these studies, responders were defined as patients who had a 50% reduction in mean weekly pain score compared with baseline.
Similar efficacy patterns were observed in this secondary endpoint.

The resubmission and IRP ( Independent Review Panel ) contains additional data from an interim, 15 month, analysis of an ongoing open-label safety study.
Patients had participated in previous Pregabalin studies and had a score of more than or equal to 40mm on the 100mm visual analogue pain scale of the SF-MPQ and were intolerant of or had experienced lack of efficacy after more than or equal to two weeks of at least minimum doses of tricyclic antidepressants, Gabapentin 1800mg or other third line agents. Patients were given Pregabalin 150-600mg daily and could continue to receive other analgesics, including those that may not have provided adequate pain control previously with titration at the investigator’s discretion to optimise pain control.
Pregabalin was discontinued quarterly for 3-28 days until patient’s pain worsened before recommencing. If pain did not worsen or only slightly deteriorated, the patient was discontinued from the study.

Interim analysis data from 45 patients with painful diabetic peripheral neuropathy and 36 patients with postherpetic neuralgia indicate that mean SF-MPQ scores decreased from respective baseline values of 73mm and 75mm to 47mm and 51mm at endpoint.

A published systematic review, new to the IRP, calculates numbers needed to treat ( NNT ) to achieve a 50% reduction in pain scores and numbers needed to harm ( NNH ) and uses these as a basis for an evidence-based treatment algorithm.
Data are included from five of the Pregabalin studies from above: three in painful diabetic peripheral neuropathy and two in postherpetic neuralgia.
The authors report a combined NNT for Pregabalin at doses of 150-600mg in both pain models of 4.2.
This is reported to be similar to the NNT for Gabapentin at all doses and pain models (5.1 ).
The NNH for Pregabalin was considered to represent a relatively high rate of withdrawal and was 11.7 compared with 26.1 for Gabapentin. For a treatment algorithm in peripheral neuropathic pain based on pain relief, the NNT are lowest for tricyclic antidepressants, then opioids, then Tramadol, then Gabapentin/Pregabalin.
 
 
 
Google
Web www.iconocast.com
 
 
 

 

ALL THE NEWS : News1 ; News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page